NON-SMALL CELL LUNG CARCINOMA
Clinical trials for NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New hope for advanced lung cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study compares a new experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive either the new drug o…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New drug targets rare cancer mutation in 300-patient trial
Disease control Recruiting nowThis study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New drug combo aims to shrink lung tumors in untreated patients
Disease control Recruiting nowThis study tests a new drug, telisotuzumab adizutecan, combined with an immunotherapy drug (a PD-1 checkpoint inhibitor) in people with advanced non-squamous non-small cell lung cancer who have not had prior treatment for advanced disease. The goal is to find the best dose that i…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Inhaled drug mist could boost lung cancer treatment before surgery
Disease control Recruiting nowThis study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug cocktail aims to outsmart resistant cancers
Disease control Recruiting nowThis study tests a new combination of two drugs (retifanlimab and ruxolitinib) in people with advanced lung or kidney cancer whose disease got worse after standard immunotherapy. The main goal is to find the safest dose of ruxolitinib when given with retifanlimab, and to see if t…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 07, 2026 18:40 UTC